Description
GFH276 is a novel therapeutic agent specifically designed for patients with RAS-mutant advanced solid tumors, including colorectal cancer. This compound represents a targeted approach to treating tumors harboring RAS mutations, which occur in approximately 40-50% of colorectal cancers and have historically been difficult to target therapeutically. The drug is currently advancing through early-phase clinical development in a tumor-agnostic approach, meaning it targets the RAS mutation regardless of the primary tumor site.
Mechanism of Action
GFH276 appears to target the RAS signaling pathway, which is frequently dysregulated in colorectal cancer through mutations in KRAS, NRAS, or other related genes. The precise molecular mechanism likely involves interference with RAS protein function or downstream signaling cascades that drive tumor cell proliferation and survival.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.